Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KMEDIUM RiskNeutral

Arvinas, Inc.

arvinas.com
Filed: Jun 22, 2026New Haven, ConnecticutCIK: 0001655759Biotechnology
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Arvinas, Inc. announced the departure of Chief Medical Officer Dr. Noah Berkowitz effective July 3, 2026, and has commenced a search for his successor. This leadership transition could impact the company's clinical and medical strategy execution.

Key Takeaways

Dr. Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, will depart Arvinas effective July 3, 2026

A separation agreement and release of claims was established between Dr. Berkowitz and the company on June 22, 2026

2 more takeaways

Related Filings (2)

2 more filings from Arvinas, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateJun 22, 2026
Item5.02
CategoryExecutive Change
CIK0001655759
Accession #arvn-20260622
Risk LevelMEDIUM
SentimentNeutral
Signalinformational
Topics
executive departureleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings